Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
StoneCo
STNE
$2.49B
| $6.55M | ﹤0.01% |
442,632
-210,500
| -32% | -$3.52M |
|
2002
Phibro Animal Health
PAHC
$1.38B
| $6.54M | ﹤0.01% |
174,944
-94,624
| -35% | -$3.84M |
|
2003
Celldex Therapeutics
CLDX
$3.35B
| $6.53M | ﹤0.01% |
240,594
-4,231
| -2% | -$111K |
|
2004
Ryanair
RYAAY
$30.7B
| $6.53M | ﹤0.01% |
90,469
+86,862
| +2,408% | +$5.65M |
|
|
REVG
2005
DELISTED
REV Group
REVG
| $6.52M | ﹤0.01% |
107,292
+33,085
| +45% | +$1.86M |
|
2006
Alarm.com
ALRM
$2.74B
| $6.52M | ﹤0.01% |
127,809
+12,522
| +11% | +$638K |
|
2007
PUT
Generac Holdings
GNRC
$12.8B
| $6.52M | ﹤0.01% |
47,800
-10,200
| -18% | -$1.65M |
|
|
APO.PRA
2008
DELISTED
Apollo Global Management Series A
APO.PRA
| $6.52M | ﹤0.01% |
86,284
+6,000
| +7% | +$419K |
|
2009
Pegasystems
PEGA
$5.51B
| $6.5M | ﹤0.01% |
108,838
-46,417
| -30% | -$2.72M |
|
2010
The Bancorp
TBBK
$2.82B
| $6.5M | ﹤0.01% |
96,249
+24,365
| +34% | +$1.68M |
|
2011
CALL
Verizon
VZ
$200B
| $6.47M | ﹤0.01% |
158,800
| – | – |
|
2012
Triple Flag Precious Metals
TFPM
$6.45B
| $6.47M | ﹤0.01% |
194,677
-15,391
| -7% | -$482K |
|
2013
BGC Group
BGC
$5.2B
| $6.46M | ﹤0.01% |
723,611
+116,313
| +19% | +$1.05M |
|
2014
First Bancorp
FBP
$4.49B
| $6.46M | ﹤0.01% |
311,552
+69,652
| +29% | +$1.44M |
|
2015
ANI Pharmaceuticals
ANIP
$1.72B
| $6.46M | ﹤0.01% |
81,790
+1,759
| +2% | +$152K |
|
2016
California Resources
CRC
$4.69B
| $6.44M | ﹤0.01% |
144,015
+36,799
| +34% | +$1.75M |
|
2017
Range Resources
RRC
$9.33B
| $6.43M | ﹤0.01% |
182,280
-70,241
| -28% | -$2.62M |
|
2018
CALL
Valley National Bancorp
VLY
$8.3B
| $6.42M | ﹤0.01% |
+550,000
| New | +$6.1M |
|
2019
Academy Sports + Outdoors
ASO
$3.03B
| $6.39M | ﹤0.01% |
127,960
+4,997
| +4% | +$248K |
|
2020
PUT
Helen of Troy
HELE
$699M
| $6.38M | ﹤0.01% |
+300,000
| New | +$6.12M |
|
2021
Winnebago Industries
WGO
$921M
| $6.36M | ﹤0.01% |
157,021
-54,534
| -26% | -$1.99M |
|
2022
Lear
LEA
$8.16B
| $6.36M | ﹤0.01% |
55,462
-24,088
| -30% | -$2.57M |
|
2023
Cimpress
CMPR
$2.37B
| $6.34M | ﹤0.01% |
95,181
+4,919
| +5% | +$334K |
|
2024
AAR Corp
AIR
$5.77B
| $6.33M | ﹤0.01% |
76,426
+10,492
| +16% | +$868K |
|
2025
Canadian Imperial Bank of Commerce
CM
$112B
| $6.32M | ﹤0.01% |
69,787
+34,010
| +95% | +$2.92M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.